Apr 7, 2026
Altria Group isn't just another tobacco stock, it's a company navigating one of the most dramatic business model transitions in modern corporate history. Understanding Altria's mission statement, vision, and core values matters for investors because these strategic declarations directly shape capital allocation, dividend sustainability, and long-term competitive positioning.
As of 2026, Altria's official purpose centers on "Moving Beyond Smoking®" by responsibly transitioning adult smokers to a smoke-free future, competing for existing smoke-free adult nicotine consumers, and exploring new growth opportunities beyond the U.S. and beyond nicotine[1]. This isn't marketing fluff; it reflects a strategic imperative driven by declining cigarette volumes and evolving consumer behavior[2].
Altria Group operates as the dominant force in U.S. tobacco, a position it has held since spinning off from Philip Morris in 2008. The company generates roughly $23.3 billion in annual revenue across three core segments: smokeable products (Marlboro, Black & Mild), oral tobacco (Copenhagen, Skoal, on! nicotine pouches), and e-vapor products (NJOY ACE and DAILY devices). What makes Altria particularly interesting for investors is that this isn't a static business; it's actively cannibalizing its most profitable product line to stay relevant.
Beyond tobacco, Altria maintains strategic investments that diversify its revenue base. The company holds an ~8.1% stake in Anheuser-Busch InBev, giving it exposure to global beverage markets, plus a position in Cronos Group for cannabis exposure. In late 2025, Altria announced a partnership with Korea's KT&G Corporation to explore non-nicotine and wellness categories, signaling ambitions that extend well beyond its historical identity.
| Metric | Figure | Context |
|---|---|---|
| 2025 Revenue | $23.3 billion | Down 3.1% YoY; traditional cigarettes declining |
| 2025 Adjusted EPS | $5.42 | Up 4.4% despite revenue headwinds |
| 2026 EPS Guidance | $5.56–$5.72 | 2.5%–5.5% projected growth |
| Marlboro Market Share | ~39.8% | Still dominant but down 1.5 points in Q4 2025 |
| OCI Margin Target | ≥60% through 2028 | Smoke-free transition funding with high profitability |
| 2025 Shareholder Returns | $8 billion | Dividends + buybacks while pivoting business model |
Altria's market position is both enviable and precarious. The company commands nearly 40% of the U.S. cigarette market through Marlboro, a brand loyalty fortress that competitors have failed to crack for decades. In oral tobacco, Copenhagen leads the moist smokeless category, while on! holds 7.7% of the total U.S. oral market despite fierce competition from Swedish Match's Zyn.
The investment thesis tension becomes clear when you look at the numbers. Altria is simultaneously managing a declining core business (smokeable volumes dropped 7.9% in Q4 2025) while building new growth engines. Oral tobacco revenues actually grew 5.9% to $753 million in Q2 2025, demonstrating that the pivot can generate actual dollars, not just press releases.
In our experience analyzing consumer defensive stocks over the past decade, companies facing structural decline often talk about transformation while harvesting cash. What distinguishes Altria is the capital commitment behind the words: $175–$225 million in 2025 capex specifically earmarked for smoke-free innovation, plus regulatory preparation expenses that don't even show up in that figure. That's real money being deployed against a real strategic challenge.
Credit agencies have taken notice. Fitch upgraded Altria to BBB+ in February 2026, citing confidence in the company's financial stability and execution capability during this transition. Analyst price targets have followed, with Barclays raising its target to $63 and Bank of America to $72, despite maintaining conservative ratings overall. The consensus isn't euphoric; it's cautiously constructive on management's ability to thread this needle.
For value investors, the key question isn't whether Altria can survive the cigarette decline. It's whether the company can convert its existing customer relationships and distribution infrastructure into competitive advantages in reduced-risk products before those advantages erode. The fact that Altria maintained 69.2% operating income margins in oral tobacco while growing that segment suggests the economics can work. Whether they work well enough to justify the current valuation is what we'll explore in the sections ahead.
Altria's official purpose is deceptively simple, but it encodes everything about how management is allocating your capital:
"Moving Beyond Smoking® by responsibly:
- Transitioning adult smokers to a smoke-free future
- Competing vigorously for existing smoke-free adult nicotine consumers
- Exploring new growth opportunities – beyond the U.S. and beyond nicotine"[^1]
You'll notice what's missing: there's no mention of "maximizing cigarette profits" or "dominating combustible tobacco." The mission has been stripped of its historical identity and rebuilt around transition, not defense.
This isn't corporate virtue signaling. The mission reflects a capital allocation framework that directly impacts dividend sustainability and long-term returns. When management says they're "competing vigorously for existing smoke-free adult nicotine consumers," they're telling you where the 2026 budget is going: heated tobacco partnerships, oral nicotine pouch expansion, and whatever comes after NJOY.
The third pillar, "beyond the U.S. and beyond nicotine," is the most interesting from an investor perspective. Altria announced a partnership with Korea's KT&G Corporation in late 2025 to explore non-nicotine wellness categories[^2]. This is exploratory capital, not core business reinvestment. Management is essentially running optionality experiments with shareholder cash.
🎯 Pro Insight: Altria's mission structure matters for valuation. The three-pillar framework gives management cover to invest in unproven categories while maintaining cash returns to shareholders. In 2025, they deployed $175–$225 million specifically for smoke-free capex[^3] while simultaneously returning $8 billion via dividends and buybacks. This dual-track capital allocation is unsustainable indefinitely, but the mission statement justifies it operationally.
The mission translates into tangible economic decisions. Oral tobacco margins hit 69.2% in Q3 2025[^4], proving the transition can be profitable. The "Moving Beyond Smoking®" framing also serves a regulatory function; it positions Altria as a harm-reduction participant rather than a purely defensive tobacco incumbent. That matters for FDA relationships and potential litigation positioning.
Compare this to how Altria might have operated 15 years ago. The company would have been maximizing Marlboro pricing power and fighting menthol restrictions. Now it's actively cannibalizing that same Marlboro franchise with on! nicotine pouches and heated tobacco development. The mission statement legitimizes what would have been heresy a decade ago.
For investors analyzing tobacco stocks in 2026, the mission clarity actually simplifies the thesis. You're not betting on cigarette volume stabilization. You're betting on whether Altria can convert its distribution infrastructure and customer relationships into competitive advantages in reduced-risk products before those advantages erode entirely.
Altria's mission isn't just a feel-good statement hanging in the lobby. It breaks down into three operational pillars that directly determine where management deploys capital, how they measure success, and what risks they're willing to take. Understanding these pillars is essential for evaluating whether Altria's strategic pivot can actually generate returns.
This is the foundation everything else builds on. Altria is explicitly trying to move its existing Marlboro customer base away from cigarettes, even though combustibles still generate the vast majority of cash flow.
The economics here are actually encouraging. Oral tobacco operating margins hit 69.2% in Q3 2025, proving that reduced-risk products can be highly profitable, not just loss-leaders for regulatory cover. The company allocated $175–$225 million in 2025 capital expenditures specifically to support this transition, funding everything from on! nicotine pouch manufacturing expansion to heated tobacco regulatory preparation.
In our experience analyzing consumer staples transitions, the companies that succeed are those that cannibalize their own products before competitors do. Altria's on! brand grew retail share to 7.7% of the total U.S. oral market despite fierce competition from Swedish Match's Zyn. That's not dominant, but it's credible progress from a standing start just a few years ago.
What matters for investors: this pillar determines whether Altria can maintain pricing power as cigarette volumes decline. If they can't convert smokers to higher-margin alternatives, the core business becomes a melting ice cube with no replacement revenue stream.
Here's where Altria's strategy gets more aggressive. They're not just transitioning their own customers; they're actively trying to steal share from competitors in categories where they have no legacy presence.
NJOY exemplifies this approach. After acquiring the e-vapor brand in 2023, Altria secured FDA market authorizations for NJOY ACE and DAILY devices, giving them regulatory legitimacy that most competitors lack. The company is now building distribution infrastructure to compete head-to-head with disposable vape brands that have captured significant market share through convenience stores and online channels.
The challenge? E-vapor remains a fragmented, promotionally intense category with persistent regulatory uncertainty. Altria's Q4 2025 earnings noted that NJOY's market position, while improving, still faces pressure from illicit products and price competition.
For investors, this pillar tests whether Altria's traditional competitive advantages, brand marketing expertise and retail relationships, translate to categories with different consumer dynamics. Early results are mixed but directionally positive.
This is Altria's optionality bet, and it's where the mission gets most interesting from a strategic perspective.
In late 2025, Altria announced a collaboration with Korea's KT&G Corporation to explore non-nicotine and wellness categories. Management explicitly framed this as "long-term adjacent growth" that won't drive near-term results but could gradually diversify the business over the next decade.
The KT&G partnership is particularly notable because it combines Altria's U.S. commercial capabilities with KT&G's product innovation in reduced-risk categories. The companies are exploring everything from heated tobacco international expansion to entirely new wellness product categories that leverage Altria's manufacturing and distribution infrastructure.
What makes this pillar strategically significant is the timing. Altria is essentially using cash flows from a declining but still highly profitable cigarette business to fund optionality experiments. If even one of these bets succeeds, the company transforms from a tobacco pure-play into something more defensible. If they all fail, the core business still generates enough cash to maintain dividends while management tries again.
The three-pillar structure isn't just organizational; it's designed to build economic moats that competitors will struggle to replicate.
| Pillar | Competitive Advantage | Economic Moat Source |
|---|---|---|
| Smoke-Free Transition | Customer relationship conversion | Marlboro's 39.8% market share provides unmatched access to adult smokers |
| Compete for Smoke-Free Consumers | Regulatory legitimacy + distribution | FDA-authorized products + 200,000+ retail relationships |
| Explore Beyond Nicotine | Financial capacity for experimentation | $8 billion annual shareholder returns while funding innovation |
The moat here isn't any single product; it's the asymmetric ability to fund multiple strategic bets simultaneously while competitors must choose between dividends and innovation. Altria returned $8 billion to shareholders in 2025 while deploying nearly a quarter-billion in smoke-free capex. That's a luxury few tobacco companies can afford.
Fitch recognized this dynamic in February 2026, upgrading Altria to BBB+ specifically citing confidence in the company's financial stability and execution capability during this transition. Credit analysts don't upgrade tobacco companies lightly; the rating improvement reflects genuine conviction that the three-pillar strategy is operationally viable, not just aspirational.
For value investors using platforms like StockIntent to screen for quality compounders, these pillars provide a framework for tracking management execution. You can monitor oral tobacco margins, NJOY market share progression, and partnership announcements as tangible evidence that the mission translates into measurable business results. The key question isn't whether Altria's mission sounds good; it's whether these pillars generate returns on invested capital that justify the stock's current valuation.
Altria's vision statement distills the company's strategic ambition into a single, forward-looking declaration:
"Moving Beyond Smoking®"
This isn't just branding. It's the organizing principle that determines how Altria deploys capital, structures partnerships, and measures management success in 2026 and beyond.
The phrase "Moving Beyond Smoking®" encodes a fundamental business reality: Altria knows the U.S. cigarette market is in structural decline. Marlboro still commands nearly 40% market share, but smokeable volumes dropped 7.9% in Q4 2025 alone. The vision acknowledges this trajectory and reframes it as opportunity rather than obsolescence.
Management has articulated three concrete ambitions flowing from this vision:
Altria's vision positions the company to capture value from several converging trends in consumer defensive stocks. The tobacco industry is experiencing what analysts call "profit pool migration" — the gradual shift of consumer spending and industry margins from combustible cigarettes to reduced-risk alternatives. Altria's vision explicitly targets this emerging profit pool rather than defending the declining one.
The vision also addresses regulatory positioning. By framing itself as a harm-reduction participant rather than a purely defensive tobacco incumbent, Altria gains strategic flexibility in FDA relationships and potential litigation contexts. This matters for long-term valuation; companies perceived as fighting structural change typically trade at lower multiples than those perceived as adapting to it.
Credit agencies have validated this positioning. Fitch upgraded Altria to BBB+ in February 2026, specifically citing confidence in the company's "financial stability and execution capability during this transition." That's not a rating you give to a melting ice cube; it's a rating you give to a management team that appears capable of navigating complex strategic change.
For investors using platforms like StockIntent to evaluate quality compounders, the vision statement provides a clear framework for tracking execution. You can monitor whether management's actions align with their words: Are oral tobacco margins expanding? Is NJOY gaining distribution? Are international partnerships generating tangible milestones? The vision creates accountability metrics that fundamental analysis can track over time.
The key insight here is that Altria's vision isn't aspirational fluff designed for annual reports. It's a capital allocation framework that justifies cannibalizing the company's most profitable product line. That takes genuine strategic conviction, and in 2026, the early evidence suggests management is backing that conviction with real resources.
Altria's "Moving Beyond Smoking®" vision isn't just a slogan; it's a capital allocation framework that determines where management deploys your investment dollars. The vision breaks down into three interconnected strategic themes that shape everything from R&D budgets to partnership decisions.
The most capital-intensive theme focuses on building competitive positions in reduced-risk products before competitors lock up market share. Altria allocated $175–$225 million in 2025 capital expenditures specifically to support this transition, funding manufacturing expansion for on! nicotine pouches, NJOY e-vapor distribution buildout, and heated tobacco regulatory preparation.
The economics are proving out. Oral tobacco operating margins hit 69.2% in Q3 2025, demonstrating that smoke-free products can generate the high returns needed to fund both innovation and shareholder returns. The on! brand now holds 7.7% of the total U.S. oral market, up from essentially zero just a few years ago.
This theme directly addresses the investor concern that Altria is a melting ice cube. If oral tobacco and e-vapor can generate comparable margins to cigarettes at scale, the business model transition becomes evolution rather than extinction.
Altria's second theme pushes beyond the geographic and category boundaries that have historically constrained the company. The KT&G Corporation partnership announced in late 2025 exemplifies this approach; it combines Altria's U.S. commercial infrastructure with KT&G's product innovation capabilities to explore international smoke-free opportunities and non-nicotine wellness categories.
Management has been explicit that this is "long-term adjacent growth" that won't drive near-term results. The company is targeting five non-nicotine products by 2028 focused on energy, focus, and stress relief. For investors, this represents optionality; if any of these categories achieve scale, Altria transforms from a tobacco pure-play into a broader consumer wellness company with entirely different valuation multiples.
The strategic logic is sound. Altria's manufacturing capabilities, regulatory expertise, and retail relationships are transferable assets. The question is whether management can execute in categories where they lack decades of consumer insight.
The third theme, often overlooked, centers on maintaining the financial flexibility to fund transformation while returning capital to shareholders. Altria returned $8 billion to shareholders in 2025 through dividends and buybacks while simultaneously deploying nearly a quarter-billion in smoke-free innovation capex.
This dual-track approach is unsustainable indefinitely if the core cigarette business deteriorates faster than smoke-free products scale. But it's strategically essential in the near term. The high dividend yield attracts income-focused investors who provide stable capital, while the buybacks reduce share count and support EPS growth even as revenue transitions between product categories.
Fitch recognized this dynamic in February 2026, upgrading Altria to BBB+ specifically citing confidence in the company's "financial stability and execution capability during this transition." Credit analysts don't upgrade tobacco companies lightly; the rating improvement reflects genuine conviction that Altria's cash flow generation can bridge the transition period.
| Strategic Theme | 2025 Capital Deployment | Key Metric | Investor Relevance |
|---|---|---|---|
| Smoke-Free Leadership | $175–$225M capex | 69.2% oral tobacco margins | Proves transition can be profitable |
| International/Adjacent | Partnership investments | 5 non-nicotine products by 2028 | Creates strategic optionality |
| Financial Capacity | $8B shareholder returns | BBB+ credit rating | Funds transformation without dilution |
The three themes work together to address the fundamental challenge facing Altria investors: how to value a business that's actively cannibalizing its most profitable product line. The smoke-free leadership theme provides near-term earnings replacement. The international/adjacent theme offers long-term growth optionality. The financial capacity theme ensures the transition doesn't require dilutive equity raises or dividend cuts that would destroy shareholder value.
For investors using platforms like StockIntent to evaluate quality compounders, these themes provide a framework for tracking management execution. You can monitor whether oral tobacco margins continue expanding, whether international partnerships generate tangible milestones, and whether the balance sheet remains strong enough to fund both dividends and innovation. The vision creates accountability; management has told you exactly what they're trying to accomplish, which makes it easier to judge whether they're succeeding.
Altria's stated core values shape how the company approaches hiring, culture, and the daily decisions that determine whether its smoke-free transition succeeds or stalls. These aren't just wall plaques; they're supposed to guide capital allocation, product development, and how management treats employees and stakeholders.
The company articulates four primary values: We Shape Our Future, We Respect Those Who Speak Up, We Care for Each Other, and We Deliver for Our Consumers and Customers, all underpinned by an overarching commitment to responsibility[1]. These sit alongside principles of Integrity, Innovation, and Collaboration that appear in corporate communications and hiring materials[2].
This value drives the proactive innovation behind Altria's smoke-free pivot. It justifies the $175–$225 million in 2025 capital expenditures for reduced-risk product development and the KT&G partnership exploring non-nicotine categories[3]. In practice, "shaping our future" means cannibalizing Marlboro, the company's profit engine, before competitors do it for them.
The tension here is real. Shaping the future requires betting against your own historical strengths. Oral tobacco margins at 69.2% in Q3 2025 suggest the economics can work[4], but management must consistently choose long-term transition over short-term cigarette optimization. That's easier to write in a values statement than to execute in quarterly earnings calls.
Altria frames this as building transparency and humility into corporate culture, encouraging employees to voice concerns and engage stakeholders openly[1]. For a company facing regulatory scrutiny and litigation risk, this value serves practical risk management. Early warning about product issues or compliance gaps can prevent costly surprises.
📌 From Our Experience: Companies in regulated industries that genuinely encourage internal pushback tend to navigate crises better than those with command-and-control cultures. Altria's history of regulatory battles, from menthol restrictions to e-vapor marketing scrutiny, makes this value operationally relevant. Whether it works in practice depends on whether middle management actually protects employees who raise red flags, or just claims to.
This value emphasizes inclusive teams, employee belonging, and acting as owners while rallying together[1]. In our experience tracking corporate transitions, companies that successfully pivot business models need employees who feel invested in outcomes, not just collecting paychecks while the ground shifts.
The challenge for Altria is that tobacco industry stigma complicates recruitment and retention, particularly for the scientific and tech talent needed for smoke-free innovation[5]. "Caring for each other" in this context means competing for talent against companies without that baggage.
This value focuses on product quality, innovation, and service that builds loyalty[1]. For investors, it's the value most directly tied to revenue. The on! nicotine pouch brand's growth to 7.7% U.S. oral market share demonstrates delivery in a competitive category[6]. NJOY's FDA market authorizations show regulatory execution that competitors struggle to match[7].
The consumer delivery metric that matters most: can Altria convert Marlboro's 39.8% cigarette market share into comparable positions in smoke-free categories before those relationships erode entirely?
Resilience threads through all four values, explicitly tied to harm reduction, underage use prevention, environmental stewardship, and sustainable supply chains[8]. This isn't altruism; it's risk management. Companies perceived as fighting structural change trade at lower multiples than those perceived as adapting to it.
Altria's environmental, social, and governance commitments extend its core values into measurable targets. The company has committed to net-zero greenhouse gas emissions across its value chain by 2050, with interim goals of 90% reduction in Scope 1 and 2 emissions by 2030 (from 2022 baseline) and no deforestation in key commodities by end of 2025[9].
These targets connect to the "We Shape Our Future" value by positioning Altria for a regulatory environment where carbon disclosure and climate risk increasingly affect capital costs and investor mandates. The sustainability commitments also serve stakeholder management; ESG-focused investors can own Altria without violating exclusionary screens, expanding the potential shareholder base.
Social responsibility programs emphasize community investment aligned with business goals, evidence-based programming, and long-term impact through partner expertise[10]. This approach, while corporate-standard, at least suggests strategic thinking about where charitable dollars generate reputational returns rather than scattered giving.
Here's where analysis gets uncomfortable. Altria's core values sound appropriate for a company in transition, but verifying genuine operationalization is harder than reading mission statements.
Positive indicators: The capital allocation matches the values rhetoric. You don't spend $175–$225 million annually on smoke-free capex while returning $8 billion to shareholders unless "shaping our future" has teeth[3]. The oral tobacco margin expansion to 69.2% proves "delivering for consumers" can generate returns[4].
Open questions: How does "respect those who speak up" function when employees identify product risks that could delay launches? Does "care for each other" extend to communities disproportionately affected by tobacco use? The values don't explicitly address harm to historical consumers, only the transition of current ones.
What we can't verify from outside: Internal culture, actual employee sentiment, and whether values training translates to decision-making when values conflict with quarterly earnings pressure. The absence of notable public failures to live up to stated values is neither proof of virtue nor evidence of problems; it may simply reflect effective reputation management.
For investors using StockIntent to evaluate quality compounders, Altria's core values provide a framework for assessing management credibility. You can track whether capital allocation aligns with "shaping our future," whether product quality metrics support "delivering for consumers," and whether regulatory compliance record reflects genuine "responsibility" or minimum legal compliance. The values create accountability metrics; whether management meets them determines whether the smoke-free transition deserves your capital.
Altria's mission, vision, and core values aren't corporate theater; they're a capital allocation framework that determines where your dividend dollars get deployed. The company's official purpose, "responsibly lead the transition of adult smokers to a smoke-free future," combined with the "Moving Beyond Smoking®" vision and values of Integrity, Responsibility, Innovation, and Collaboration, creates a coherent strategic identity for investors to evaluate [1].
💡 Expert Tip: When analyzing mission-driven companies, always check whether stated values appear in capital allocation decisions. Altria's $175–$225 million annual smoke-free capex commitment, alongside $8 billion in 2025 shareholder returns, proves management is backing their words with real dollars. Companies that talk transformation without deploying capital are usually harvesting, not pivoting.
The connection between Altria's stated strategy and competitive positioning shows up in three concrete areas:
Competitive Positioning and Economic Moats
Altria's strategic pillars, transition existing smokers, compete for smoke-free consumers, and explore beyond nicotine, leverage existing advantages that competitors struggle to replicate. Marlboro's 39.8% U.S. cigarette market share provides unmatched customer access for conversion [2]. Oral tobacco margins hit 69.2% in Q3 2025, proving the transition can generate returns that support the dividend [3]. The KT&G partnership for international and non-nicotine expansion creates optionality without requiring core business reinvestment [4].
Management Quality Signals
Credit agencies have validated execution capability. Fitch upgraded Altria to BBB+ in February 2026, specifically citing "confidence in the company's financial stability and execution capability during this transition" [5]. That's not routine for tobacco companies. Similarly, analyst price target increases, Barclays to $63 and Bank of America to $72, reflect conviction that management can thread the needle between decline management and growth investment [6].
In our experience analyzing consumer defensive transitions over the past decade, companies that successfully pivot typically show three patterns: they cannibalize their own products before competitors do, they maintain financial capacity to fund both transformation and shareholder returns, and they earn validation from skeptical third parties like credit rating agencies. Altria checks all three boxes.
Long-Term Compounding Potential
The analyst consensus holds a cautiously constructive view. Across major coverage, ratings split roughly 4 Buys, 5 Holds, and 2 Sells, with average price targets around $60–$63 implying modest upside from current levels [7]. The long-term thesis isn't about explosive growth; it's about whether Altria can convert its existing customer relationships and distribution infrastructure into sustainable competitive advantages in reduced-risk products before those advantages erode entirely.
| Strategic Element | Investment Relevance | 2026 Evidence |
|---|---|---|
| Mission clarity | Guides capital allocation visibility | $175–$225M smoke-free capex commitment |
| Vision execution | Determines earnings replacement timing | Oral tobacco 69.2% margins, 7.7% on! share |
| Values alignment | Signals management credibility | BBB+ Fitch upgrade, analyst target increases |
| Competitive moat | Sustains pricing power through transition | Marlboro access, FDA-authorized NJOY products |
Looking ahead, Altria's strategic framework positions the company for a bifurcated future. If smoke-free products scale profitably and international partnerships generate traction, the company transforms from a declining tobacco pure-play into a more defensible consumer wellness business with entirely different valuation multiples. If the transition stalls, the core cigarette franchise still generates sufficient cash flow to maintain dividends for years, albeit with shrinking terminal value.
The key variable isn't whether Altria's mission sounds good on paper. It's whether the three-pillar execution framework generates returns on invested capital that justify the stock's current valuation. For investors using platforms like StockIntent to evaluate quality compounders, Altria's strategic identity provides clear metrics to track: oral tobacco margin progression, NJOY market share gains, and international partnership milestones. You can try StockIntent totally risk-free for 7 days to screen for companies with similar mission-to-execution alignment in your own portfolio.
The bottom line? Altria's mission, vision, and values create accountability. Management has told you exactly what they're trying to accomplish, which makes it easier to judge whether they're succeeding. That's more than most companies facing structural decline provide.
Altria Group isn't just another tobacco stock, it's a company navigating one of the most dramatic business model transitions in modern corporate history. Understanding Altria's mission statement, vision, and core values matters for investors because these strategic declarations directly shape capital allocation, dividend sustainability, and long-term competitive positioning.
As of 2026, Altria's official purpose centers on "Moving Beyond Smoking®" by responsibly transitioning adult smokers to a smoke-free future, competing for existing smoke-free adult nicotine consumers, and exploring new growth opportunities beyond the U.S. and beyond nicotine[1]. This isn't marketing fluff; it reflects a strategic imperative driven by declining cigarette volumes and evolving consumer behavior[2].
Altria Group operates as the dominant force in U.S. tobacco, a position it has held since spinning off from Philip Morris in 2008. The company generates roughly $23.3 billion in annual revenue across three core segments: smokeable products (Marlboro, Black & Mild), oral tobacco (Copenhagen, Skoal, on! nicotine pouches), and e-vapor products (NJOY ACE and DAILY devices). What makes Altria particularly interesting for investors is that this isn't a static business; it's actively cannibalizing its most profitable product line to stay relevant.
Beyond tobacco, Altria maintains strategic investments that diversify its revenue base. The company holds an ~8.1% stake in Anheuser-Busch InBev, giving it exposure to global beverage markets, plus a position in Cronos Group for cannabis exposure. In late 2025, Altria announced a partnership with Korea's KT&G Corporation to explore non-nicotine and wellness categories, signaling ambitions that extend well beyond its historical identity.
| Metric | Figure | Context |
|---|---|---|
| 2025 Revenue | $23.3 billion | Down 3.1% YoY; traditional cigarettes declining |
| 2025 Adjusted EPS | $5.42 | Up 4.4% despite revenue headwinds |
| 2026 EPS Guidance | $5.56–$5.72 | 2.5%–5.5% projected growth |
| Marlboro Market Share | ~39.8% | Still dominant but down 1.5 points in Q4 2025 |
| OCI Margin Target | ≥60% through 2028 | Smoke-free transition funding with high profitability |
| 2025 Shareholder Returns | $8 billion | Dividends + buybacks while pivoting business model |
Altria's market position is both enviable and precarious. The company commands nearly 40% of the U.S. cigarette market through Marlboro, a brand loyalty fortress that competitors have failed to crack for decades. In oral tobacco, Copenhagen leads the moist smokeless category, while on! holds 7.7% of the total U.S. oral market despite fierce competition from Swedish Match's Zyn.
The investment thesis tension becomes clear when you look at the numbers. Altria is simultaneously managing a declining core business (smokeable volumes dropped 7.9% in Q4 2025) while building new growth engines. Oral tobacco revenues actually grew 5.9% to $753 million in Q2 2025, demonstrating that the pivot can generate actual dollars, not just press releases.
In our experience analyzing consumer defensive stocks over the past decade, companies facing structural decline often talk about transformation while harvesting cash. What distinguishes Altria is the capital commitment behind the words: $175–$225 million in 2025 capex specifically earmarked for smoke-free innovation, plus regulatory preparation expenses that don't even show up in that figure. That's real money being deployed against a real strategic challenge.
Credit agencies have taken notice. Fitch upgraded Altria to BBB+ in February 2026, citing confidence in the company's financial stability and execution capability during this transition. Analyst price targets have followed, with Barclays raising its target to $63 and Bank of America to $72, despite maintaining conservative ratings overall. The consensus isn't euphoric; it's cautiously constructive on management's ability to thread this needle.
For value investors, the key question isn't whether Altria can survive the cigarette decline. It's whether the company can convert its existing customer relationships and distribution infrastructure into competitive advantages in reduced-risk products before those advantages erode. The fact that Altria maintained 69.2% operating income margins in oral tobacco while growing that segment suggests the economics can work. Whether they work well enough to justify the current valuation is what we'll explore in the sections ahead.
Altria's official purpose is deceptively simple, but it encodes everything about how management is allocating your capital:
"Moving Beyond Smoking® by responsibly:
- Transitioning adult smokers to a smoke-free future
- Competing vigorously for existing smoke-free adult nicotine consumers
- Exploring new growth opportunities – beyond the U.S. and beyond nicotine"[^1]
You'll notice what's missing: there's no mention of "maximizing cigarette profits" or "dominating combustible tobacco." The mission has been stripped of its historical identity and rebuilt around transition, not defense.
This isn't corporate virtue signaling. The mission reflects a capital allocation framework that directly impacts dividend sustainability and long-term returns. When management says they're "competing vigorously for existing smoke-free adult nicotine consumers," they're telling you where the 2026 budget is going: heated tobacco partnerships, oral nicotine pouch expansion, and whatever comes after NJOY.
The third pillar, "beyond the U.S. and beyond nicotine," is the most interesting from an investor perspective. Altria announced a partnership with Korea's KT&G Corporation in late 2025 to explore non-nicotine wellness categories[^2]. This is exploratory capital, not core business reinvestment. Management is essentially running optionality experiments with shareholder cash.
🎯 Pro Insight: Altria's mission structure matters for valuation. The three-pillar framework gives management cover to invest in unproven categories while maintaining cash returns to shareholders. In 2025, they deployed $175–$225 million specifically for smoke-free capex[^3] while simultaneously returning $8 billion via dividends and buybacks. This dual-track capital allocation is unsustainable indefinitely, but the mission statement justifies it operationally.
The mission translates into tangible economic decisions. Oral tobacco margins hit 69.2% in Q3 2025[^4], proving the transition can be profitable. The "Moving Beyond Smoking®" framing also serves a regulatory function; it positions Altria as a harm-reduction participant rather than a purely defensive tobacco incumbent. That matters for FDA relationships and potential litigation positioning.
Compare this to how Altria might have operated 15 years ago. The company would have been maximizing Marlboro pricing power and fighting menthol restrictions. Now it's actively cannibalizing that same Marlboro franchise with on! nicotine pouches and heated tobacco development. The mission statement legitimizes what would have been heresy a decade ago.
For investors analyzing tobacco stocks in 2026, the mission clarity actually simplifies the thesis. You're not betting on cigarette volume stabilization. You're betting on whether Altria can convert its distribution infrastructure and customer relationships into competitive advantages in reduced-risk products before those advantages erode entirely.
Altria's mission isn't just a feel-good statement hanging in the lobby. It breaks down into three operational pillars that directly determine where management deploys capital, how they measure success, and what risks they're willing to take. Understanding these pillars is essential for evaluating whether Altria's strategic pivot can actually generate returns.
This is the foundation everything else builds on. Altria is explicitly trying to move its existing Marlboro customer base away from cigarettes, even though combustibles still generate the vast majority of cash flow.
The economics here are actually encouraging. Oral tobacco operating margins hit 69.2% in Q3 2025, proving that reduced-risk products can be highly profitable, not just loss-leaders for regulatory cover. The company allocated $175–$225 million in 2025 capital expenditures specifically to support this transition, funding everything from on! nicotine pouch manufacturing expansion to heated tobacco regulatory preparation.
In our experience analyzing consumer staples transitions, the companies that succeed are those that cannibalize their own products before competitors do. Altria's on! brand grew retail share to 7.7% of the total U.S. oral market despite fierce competition from Swedish Match's Zyn. That's not dominant, but it's credible progress from a standing start just a few years ago.
What matters for investors: this pillar determines whether Altria can maintain pricing power as cigarette volumes decline. If they can't convert smokers to higher-margin alternatives, the core business becomes a melting ice cube with no replacement revenue stream.
Here's where Altria's strategy gets more aggressive. They're not just transitioning their own customers; they're actively trying to steal share from competitors in categories where they have no legacy presence.
NJOY exemplifies this approach. After acquiring the e-vapor brand in 2023, Altria secured FDA market authorizations for NJOY ACE and DAILY devices, giving them regulatory legitimacy that most competitors lack. The company is now building distribution infrastructure to compete head-to-head with disposable vape brands that have captured significant market share through convenience stores and online channels.
The challenge? E-vapor remains a fragmented, promotionally intense category with persistent regulatory uncertainty. Altria's Q4 2025 earnings noted that NJOY's market position, while improving, still faces pressure from illicit products and price competition.
For investors, this pillar tests whether Altria's traditional competitive advantages, brand marketing expertise and retail relationships, translate to categories with different consumer dynamics. Early results are mixed but directionally positive.
This is Altria's optionality bet, and it's where the mission gets most interesting from a strategic perspective.
In late 2025, Altria announced a collaboration with Korea's KT&G Corporation to explore non-nicotine and wellness categories. Management explicitly framed this as "long-term adjacent growth" that won't drive near-term results but could gradually diversify the business over the next decade.
The KT&G partnership is particularly notable because it combines Altria's U.S. commercial capabilities with KT&G's product innovation in reduced-risk categories. The companies are exploring everything from heated tobacco international expansion to entirely new wellness product categories that leverage Altria's manufacturing and distribution infrastructure.
What makes this pillar strategically significant is the timing. Altria is essentially using cash flows from a declining but still highly profitable cigarette business to fund optionality experiments. If even one of these bets succeeds, the company transforms from a tobacco pure-play into something more defensible. If they all fail, the core business still generates enough cash to maintain dividends while management tries again.
The three-pillar structure isn't just organizational; it's designed to build economic moats that competitors will struggle to replicate.
| Pillar | Competitive Advantage | Economic Moat Source |
|---|---|---|
| Smoke-Free Transition | Customer relationship conversion | Marlboro's 39.8% market share provides unmatched access to adult smokers |
| Compete for Smoke-Free Consumers | Regulatory legitimacy + distribution | FDA-authorized products + 200,000+ retail relationships |
| Explore Beyond Nicotine | Financial capacity for experimentation | $8 billion annual shareholder returns while funding innovation |
The moat here isn't any single product; it's the asymmetric ability to fund multiple strategic bets simultaneously while competitors must choose between dividends and innovation. Altria returned $8 billion to shareholders in 2025 while deploying nearly a quarter-billion in smoke-free capex. That's a luxury few tobacco companies can afford.
Fitch recognized this dynamic in February 2026, upgrading Altria to BBB+ specifically citing confidence in the company's financial stability and execution capability during this transition. Credit analysts don't upgrade tobacco companies lightly; the rating improvement reflects genuine conviction that the three-pillar strategy is operationally viable, not just aspirational.
For value investors using platforms like StockIntent to screen for quality compounders, these pillars provide a framework for tracking management execution. You can monitor oral tobacco margins, NJOY market share progression, and partnership announcements as tangible evidence that the mission translates into measurable business results. The key question isn't whether Altria's mission sounds good; it's whether these pillars generate returns on invested capital that justify the stock's current valuation.
Altria's vision statement distills the company's strategic ambition into a single, forward-looking declaration:
"Moving Beyond Smoking®"
This isn't just branding. It's the organizing principle that determines how Altria deploys capital, structures partnerships, and measures management success in 2026 and beyond.
The phrase "Moving Beyond Smoking®" encodes a fundamental business reality: Altria knows the U.S. cigarette market is in structural decline. Marlboro still commands nearly 40% market share, but smokeable volumes dropped 7.9% in Q4 2025 alone. The vision acknowledges this trajectory and reframes it as opportunity rather than obsolescence.
Management has articulated three concrete ambitions flowing from this vision:
Altria's vision positions the company to capture value from several converging trends in consumer defensive stocks. The tobacco industry is experiencing what analysts call "profit pool migration" — the gradual shift of consumer spending and industry margins from combustible cigarettes to reduced-risk alternatives. Altria's vision explicitly targets this emerging profit pool rather than defending the declining one.
The vision also addresses regulatory positioning. By framing itself as a harm-reduction participant rather than a purely defensive tobacco incumbent, Altria gains strategic flexibility in FDA relationships and potential litigation contexts. This matters for long-term valuation; companies perceived as fighting structural change typically trade at lower multiples than those perceived as adapting to it.
Credit agencies have validated this positioning. Fitch upgraded Altria to BBB+ in February 2026, specifically citing confidence in the company's "financial stability and execution capability during this transition." That's not a rating you give to a melting ice cube; it's a rating you give to a management team that appears capable of navigating complex strategic change.
For investors using platforms like StockIntent to evaluate quality compounders, the vision statement provides a clear framework for tracking execution. You can monitor whether management's actions align with their words: Are oral tobacco margins expanding? Is NJOY gaining distribution? Are international partnerships generating tangible milestones? The vision creates accountability metrics that fundamental analysis can track over time.
The key insight here is that Altria's vision isn't aspirational fluff designed for annual reports. It's a capital allocation framework that justifies cannibalizing the company's most profitable product line. That takes genuine strategic conviction, and in 2026, the early evidence suggests management is backing that conviction with real resources.
Altria's "Moving Beyond Smoking®" vision isn't just a slogan; it's a capital allocation framework that determines where management deploys your investment dollars. The vision breaks down into three interconnected strategic themes that shape everything from R&D budgets to partnership decisions.
The most capital-intensive theme focuses on building competitive positions in reduced-risk products before competitors lock up market share. Altria allocated $175–$225 million in 2025 capital expenditures specifically to support this transition, funding manufacturing expansion for on! nicotine pouches, NJOY e-vapor distribution buildout, and heated tobacco regulatory preparation.
The economics are proving out. Oral tobacco operating margins hit 69.2% in Q3 2025, demonstrating that smoke-free products can generate the high returns needed to fund both innovation and shareholder returns. The on! brand now holds 7.7% of the total U.S. oral market, up from essentially zero just a few years ago.
This theme directly addresses the investor concern that Altria is a melting ice cube. If oral tobacco and e-vapor can generate comparable margins to cigarettes at scale, the business model transition becomes evolution rather than extinction.
Altria's second theme pushes beyond the geographic and category boundaries that have historically constrained the company. The KT&G Corporation partnership announced in late 2025 exemplifies this approach; it combines Altria's U.S. commercial infrastructure with KT&G's product innovation capabilities to explore international smoke-free opportunities and non-nicotine wellness categories.
Management has been explicit that this is "long-term adjacent growth" that won't drive near-term results. The company is targeting five non-nicotine products by 2028 focused on energy, focus, and stress relief. For investors, this represents optionality; if any of these categories achieve scale, Altria transforms from a tobacco pure-play into a broader consumer wellness company with entirely different valuation multiples.
The strategic logic is sound. Altria's manufacturing capabilities, regulatory expertise, and retail relationships are transferable assets. The question is whether management can execute in categories where they lack decades of consumer insight.
The third theme, often overlooked, centers on maintaining the financial flexibility to fund transformation while returning capital to shareholders. Altria returned $8 billion to shareholders in 2025 through dividends and buybacks while simultaneously deploying nearly a quarter-billion in smoke-free innovation capex.
This dual-track approach is unsustainable indefinitely if the core cigarette business deteriorates faster than smoke-free products scale. But it's strategically essential in the near term. The high dividend yield attracts income-focused investors who provide stable capital, while the buybacks reduce share count and support EPS growth even as revenue transitions between product categories.
Fitch recognized this dynamic in February 2026, upgrading Altria to BBB+ specifically citing confidence in the company's "financial stability and execution capability during this transition." Credit analysts don't upgrade tobacco companies lightly; the rating improvement reflects genuine conviction that Altria's cash flow generation can bridge the transition period.
| Strategic Theme | 2025 Capital Deployment | Key Metric | Investor Relevance |
|---|---|---|---|
| Smoke-Free Leadership | $175–$225M capex | 69.2% oral tobacco margins | Proves transition can be profitable |
| International/Adjacent | Partnership investments | 5 non-nicotine products by 2028 | Creates strategic optionality |
| Financial Capacity | $8B shareholder returns | BBB+ credit rating | Funds transformation without dilution |
The three themes work together to address the fundamental challenge facing Altria investors: how to value a business that's actively cannibalizing its most profitable product line. The smoke-free leadership theme provides near-term earnings replacement. The international/adjacent theme offers long-term growth optionality. The financial capacity theme ensures the transition doesn't require dilutive equity raises or dividend cuts that would destroy shareholder value.
For investors using platforms like StockIntent to evaluate quality compounders, these themes provide a framework for tracking management execution. You can monitor whether oral tobacco margins continue expanding, whether international partnerships generate tangible milestones, and whether the balance sheet remains strong enough to fund both dividends and innovation. The vision creates accountability; management has told you exactly what they're trying to accomplish, which makes it easier to judge whether they're succeeding.
Altria's stated core values shape how the company approaches hiring, culture, and the daily decisions that determine whether its smoke-free transition succeeds or stalls. These aren't just wall plaques; they're supposed to guide capital allocation, product development, and how management treats employees and stakeholders.
The company articulates four primary values: We Shape Our Future, We Respect Those Who Speak Up, We Care for Each Other, and We Deliver for Our Consumers and Customers, all underpinned by an overarching commitment to responsibility[1]. These sit alongside principles of Integrity, Innovation, and Collaboration that appear in corporate communications and hiring materials[2].
This value drives the proactive innovation behind Altria's smoke-free pivot. It justifies the $175–$225 million in 2025 capital expenditures for reduced-risk product development and the KT&G partnership exploring non-nicotine categories[3]. In practice, "shaping our future" means cannibalizing Marlboro, the company's profit engine, before competitors do it for them.
The tension here is real. Shaping the future requires betting against your own historical strengths. Oral tobacco margins at 69.2% in Q3 2025 suggest the economics can work[4], but management must consistently choose long-term transition over short-term cigarette optimization. That's easier to write in a values statement than to execute in quarterly earnings calls.
Altria frames this as building transparency and humility into corporate culture, encouraging employees to voice concerns and engage stakeholders openly[1]. For a company facing regulatory scrutiny and litigation risk, this value serves practical risk management. Early warning about product issues or compliance gaps can prevent costly surprises.
📌 From Our Experience: Companies in regulated industries that genuinely encourage internal pushback tend to navigate crises better than those with command-and-control cultures. Altria's history of regulatory battles, from menthol restrictions to e-vapor marketing scrutiny, makes this value operationally relevant. Whether it works in practice depends on whether middle management actually protects employees who raise red flags, or just claims to.
This value emphasizes inclusive teams, employee belonging, and acting as owners while rallying together[1]. In our experience tracking corporate transitions, companies that successfully pivot business models need employees who feel invested in outcomes, not just collecting paychecks while the ground shifts.
The challenge for Altria is that tobacco industry stigma complicates recruitment and retention, particularly for the scientific and tech talent needed for smoke-free innovation[5]. "Caring for each other" in this context means competing for talent against companies without that baggage.
This value focuses on product quality, innovation, and service that builds loyalty[1]. For investors, it's the value most directly tied to revenue. The on! nicotine pouch brand's growth to 7.7% U.S. oral market share demonstrates delivery in a competitive category[6]. NJOY's FDA market authorizations show regulatory execution that competitors struggle to match[7].
The consumer delivery metric that matters most: can Altria convert Marlboro's 39.8% cigarette market share into comparable positions in smoke-free categories before those relationships erode entirely?
Resilience threads through all four values, explicitly tied to harm reduction, underage use prevention, environmental stewardship, and sustainable supply chains[8]. This isn't altruism; it's risk management. Companies perceived as fighting structural change trade at lower multiples than those perceived as adapting to it.
Altria's environmental, social, and governance commitments extend its core values into measurable targets. The company has committed to net-zero greenhouse gas emissions across its value chain by 2050, with interim goals of 90% reduction in Scope 1 and 2 emissions by 2030 (from 2022 baseline) and no deforestation in key commodities by end of 2025[9].
These targets connect to the "We Shape Our Future" value by positioning Altria for a regulatory environment where carbon disclosure and climate risk increasingly affect capital costs and investor mandates. The sustainability commitments also serve stakeholder management; ESG-focused investors can own Altria without violating exclusionary screens, expanding the potential shareholder base.
Social responsibility programs emphasize community investment aligned with business goals, evidence-based programming, and long-term impact through partner expertise[10]. This approach, while corporate-standard, at least suggests strategic thinking about where charitable dollars generate reputational returns rather than scattered giving.
Here's where analysis gets uncomfortable. Altria's core values sound appropriate for a company in transition, but verifying genuine operationalization is harder than reading mission statements.
Positive indicators: The capital allocation matches the values rhetoric. You don't spend $175–$225 million annually on smoke-free capex while returning $8 billion to shareholders unless "shaping our future" has teeth[3]. The oral tobacco margin expansion to 69.2% proves "delivering for consumers" can generate returns[4].
Open questions: How does "respect those who speak up" function when employees identify product risks that could delay launches? Does "care for each other" extend to communities disproportionately affected by tobacco use? The values don't explicitly address harm to historical consumers, only the transition of current ones.
What we can't verify from outside: Internal culture, actual employee sentiment, and whether values training translates to decision-making when values conflict with quarterly earnings pressure. The absence of notable public failures to live up to stated values is neither proof of virtue nor evidence of problems; it may simply reflect effective reputation management.
For investors using StockIntent to evaluate quality compounders, Altria's core values provide a framework for assessing management credibility. You can track whether capital allocation aligns with "shaping our future," whether product quality metrics support "delivering for consumers," and whether regulatory compliance record reflects genuine "responsibility" or minimum legal compliance. The values create accountability metrics; whether management meets them determines whether the smoke-free transition deserves your capital.
Altria's mission, vision, and core values aren't corporate theater; they're a capital allocation framework that determines where your dividend dollars get deployed. The company's official purpose, "responsibly lead the transition of adult smokers to a smoke-free future," combined with the "Moving Beyond Smoking®" vision and values of Integrity, Responsibility, Innovation, and Collaboration, creates a coherent strategic identity for investors to evaluate [1].
💡 Expert Tip: When analyzing mission-driven companies, always check whether stated values appear in capital allocation decisions. Altria's $175–$225 million annual smoke-free capex commitment, alongside $8 billion in 2025 shareholder returns, proves management is backing their words with real dollars. Companies that talk transformation without deploying capital are usually harvesting, not pivoting.
The connection between Altria's stated strategy and competitive positioning shows up in three concrete areas:
Competitive Positioning and Economic Moats
Altria's strategic pillars, transition existing smokers, compete for smoke-free consumers, and explore beyond nicotine, leverage existing advantages that competitors struggle to replicate. Marlboro's 39.8% U.S. cigarette market share provides unmatched customer access for conversion [2]. Oral tobacco margins hit 69.2% in Q3 2025, proving the transition can generate returns that support the dividend [3]. The KT&G partnership for international and non-nicotine expansion creates optionality without requiring core business reinvestment [4].
Management Quality Signals
Credit agencies have validated execution capability. Fitch upgraded Altria to BBB+ in February 2026, specifically citing "confidence in the company's financial stability and execution capability during this transition" [5]. That's not routine for tobacco companies. Similarly, analyst price target increases, Barclays to $63 and Bank of America to $72, reflect conviction that management can thread the needle between decline management and growth investment [6].
In our experience analyzing consumer defensive transitions over the past decade, companies that successfully pivot typically show three patterns: they cannibalize their own products before competitors do, they maintain financial capacity to fund both transformation and shareholder returns, and they earn validation from skeptical third parties like credit rating agencies. Altria checks all three boxes.
Long-Term Compounding Potential
The analyst consensus holds a cautiously constructive view. Across major coverage, ratings split roughly 4 Buys, 5 Holds, and 2 Sells, with average price targets around $60–$63 implying modest upside from current levels [7]. The long-term thesis isn't about explosive growth; it's about whether Altria can convert its existing customer relationships and distribution infrastructure into sustainable competitive advantages in reduced-risk products before those advantages erode entirely.
| Strategic Element | Investment Relevance | 2026 Evidence |
|---|---|---|
| Mission clarity | Guides capital allocation visibility | $175–$225M smoke-free capex commitment |
| Vision execution | Determines earnings replacement timing | Oral tobacco 69.2% margins, 7.7% on! share |
| Values alignment | Signals management credibility | BBB+ Fitch upgrade, analyst target increases |
| Competitive moat | Sustains pricing power through transition | Marlboro access, FDA-authorized NJOY products |
Looking ahead, Altria's strategic framework positions the company for a bifurcated future. If smoke-free products scale profitably and international partnerships generate traction, the company transforms from a declining tobacco pure-play into a more defensible consumer wellness business with entirely different valuation multiples. If the transition stalls, the core cigarette franchise still generates sufficient cash flow to maintain dividends for years, albeit with shrinking terminal value.
The key variable isn't whether Altria's mission sounds good on paper. It's whether the three-pillar execution framework generates returns on invested capital that justify the stock's current valuation. For investors using platforms like StockIntent to evaluate quality compounders, Altria's strategic identity provides clear metrics to track: oral tobacco margin progression, NJOY market share gains, and international partnership milestones. You can try StockIntent totally risk-free for 7 days to screen for companies with similar mission-to-execution alignment in your own portfolio.
The bottom line? Altria's mission, vision, and values create accountability. Management has told you exactly what they're trying to accomplish, which makes it easier to judge whether they're succeeding. That's more than most companies facing structural decline provide.